Fresenius Offers First And Only Canadian Tocilizumab Biosimilar
Kabi’s Tyenne Once Again Takes Pole Position Among Actemra Rivals
Fresenius Kabi has claimed another first for its Tyenne biosimilar rival to Actemra, becoming the debut challenger to the rheumatoid arthritis treatment to launch in Canada.
